ABT vs ADP Stock Comparison

Scores Breakdown

Metric	ABT	ADP
📈 Growth	18/30	26/30
💰 Profitability	17/20	18/20
🏦 Financial Health	18/20	12/20
💵 Valuation	12/20	14/20
⚠️ Risk (lower is better)	4/10	6/10
Overall Score	71/100	74/100

Side-by-Side Summaries

ABT Analysis	ADP Analysis
📈 Growth & Financial Trajectory Across the observed quarters from 2024-Q2 through 2026-Q2 Abbott Laboratories shows an 8-quarter style revenue uptick, with Revenues rising from about $10.635B to $12.593B (+~~18%). Net income fluctuates, starting around $1.306B and ending near $0.928B, signaling earnings volatility despite top-line strength. Operating income remains solid (~~$1.69B in 2026-Q2) and gross margins stay in the high-50s, roughly a Gross Margin of 57–58%. Cash generation is resilient: quarterly operating cash flow from continuing activities was strong (e.g., around $2.49B in 2026-Q2), but total net cash flow swung negative in some periods due to financing activity, yielding a negative net cash flow of about $1.70B. 💰 Margins & Cash Flow Gross Margin: high-50s to ~58%; Operating Margin around 13–14% in the latest quarter. Operating cash flow from continuing activities generally robust; Net cash flow can be negative when financing activity dominates, as seen in 2026-Q2 (-$1.70B). 🛡️ Balance Sheet & Liquidity Total assets approx $109B with Equity around $51.8B and Liabilities near $57.5B. Current assets vs current liabilities yields a Current ratio near 1.38, indicating solid liquidity. Leverage is moderate given the equity base and stable cash flow. ⚠️ Key Drivers & Risks Drivers: Diversified product portfolio supporting recurring revenues; demand for diagnostics and chronic-care management. Risks: Earnings volatility across quarters; cash flow sensitivity to financing activities and potential regulatory/currency shifts.	📈 Growth & Financial Trajectory Over the 8 quarters, revenues rose from about $4.77B (2024 Q4) to about $5.36B (2026 Q4). Net income progressed from roughly $0.83B to $1.06B, a 28% increase, signaling earnings leverage as the top line expanded. The quarterly path fluctuated—peaking near $5.55B in 2025 Q3/Q4 before settling in the $5.2–$5.36B range—yet the trend remains clearly positive. The Gross Margin held in the high-40s to mid-50s, while Operating Margin stayed in the low- to mid-20s, underpinning a solid profitability trajectory. 💰 Margins & Cash Flow Gross Margin: roughly 46–56% across periods, with a peak around 56%. Operating Margin: generally 20–24%, supporting meaningful operating leverage. Net cash flow from operating activities was consistently positive in most quarters, while investing cash flow was mostly modestly negative and financing activity contributed steady liquidity. 🛡️ Balance Sheet & Liquidity Current assets ($52B) vs current liabilities ($50B) yields a tight but adequate liquidity cushion. Liabilities ($57B) exceed equity ($6B), indicating leverage, but assets and ongoing operating cash flows provide resilience. The balance sheet remains stable with a solid asset base. ⚠️ Key Drivers & Risks Drivers: Recurring payroll/data-processing demand; large installed base and stable cash flows. Risks: Valuation sensitivity to growth momentum; exposure to regulatory shifts or macro cycles.

ABT Analysis

ADP Analysis

📈 Growth & Financial Trajectory

Across the observed quarters from 2024-Q2 through 2026-Q2 Abbott Laboratories shows an 8-quarter style revenue uptick, with Revenues rising from about $10.635B to $12.593B (+~~18%). Net income fluctuates, starting around $1.306B and ending near $0.928B, signaling earnings volatility despite top-line strength. Operating income remains solid (~~$1.69B in 2026-Q2) and gross margins stay in the high-50s, roughly a Gross Margin of 57–58%. Cash generation is resilient: quarterly operating cash flow from continuing activities was strong (e.g., around $2.49B in 2026-Q2), but total net cash flow swung negative in some periods due to financing activity, yielding a negative net cash flow of about $1.70B.

💰 Margins & Cash Flow

Gross Margin: high-50s to ~58%; Operating Margin around 13–14% in the latest quarter.
Operating cash flow from continuing activities generally robust; Net cash flow can be negative when financing activity dominates, as seen in 2026-Q2 (-$1.70B).

🛡️ Balance Sheet & Liquidity

Total assets approx $109B with Equity around $51.8B and Liabilities near $57.5B. Current assets vs current liabilities yields a Current ratio near 1.38, indicating solid liquidity. Leverage is moderate given the equity base and stable cash flow.

⚠️ Key Drivers & Risks

Drivers: Diversified product portfolio supporting recurring revenues; demand for diagnostics and chronic-care management.
Risks: Earnings volatility across quarters; cash flow sensitivity to financing activities and potential regulatory/currency shifts.

📈 Growth & Financial Trajectory

Over the 8 quarters, revenues rose from about $4.77B (2024 Q4) to about $5.36B (2026 Q4). Net income progressed from roughly $0.83B to $1.06B, a 28% increase, signaling earnings leverage as the top line expanded. The quarterly path fluctuated—peaking near $5.55B in 2025 Q3/Q4 before settling in the $5.2–$5.36B range—yet the trend remains clearly positive. The Gross Margin held in the high-40s to mid-50s, while Operating Margin stayed in the low- to mid-20s, underpinning a solid profitability trajectory.

💰 Margins & Cash Flow

Gross Margin: roughly 46–56% across periods, with a peak around 56%.
Operating Margin: generally 20–24%, supporting meaningful operating leverage.
Net cash flow from operating activities was consistently positive in most quarters, while investing cash flow was mostly modestly negative and financing activity contributed steady liquidity.

🛡️ Balance Sheet & Liquidity

Current assets ($52B) vs current liabilities ($50B) yields a tight but adequate liquidity cushion.
Liabilities ($57B) exceed equity ($6B), indicating leverage, but assets and ongoing operating cash flows provide resilience. The balance sheet remains stable with a solid asset base.

⚠️ Key Drivers & Risks

Drivers: Recurring payroll/data-processing demand; large installed base and stable cash flows.
Risks: Valuation sensitivity to growth momentum; exposure to regulatory shifts or macro cycles.

Similar Companies

ABBV Score: 64 BSX Score: 79 DXCM Score: 82 ELV Score: 62 ISRG Score: 84 JNJ Score: 86 MDT Score: 78 TMO Score: 75 TSLA Score: 64

Top Rated Companies

View Top 20 →

TPL "Texas Pacific Land Corp"

MPWR "MONOLITHIC POWER SYSTEMS, INC."

AMD "ADVANCED MICRO DEVICES INC"

KO "COCA COLA CO"

TEL "TE Connectivity plc"